UCBJF:OTCMKTS
UCB SA
$235.94
arrow_downward
-1.03%(-2.46) 1D
Oct 13, 10:35:17 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
$235.94
High
$235.94
Low
$235.94
Mkt. cap
39.20B
Avg. vol.
140.00
Volume
61.00
52-wk high
$345.39
52-wk low
$219.60
Beta
0.58
Shares outstanding
194.51M
No. of employees
9K
Open
$235.94
High
$235.94
Low
$235.94
Mkt. cap
39.20B
Avg. vol.
140.00
Volume
61.00
52-wk high
$345.39
52-wk low
$219.60
Beta
0.58
Shares outstanding
194.51M
No. of employees
9K
News stories
From web sources and news partners
ad-hoc-news.de
·
8 hours ago
ING sets EUR 304.00 target for UCB stock with 48.87 percent upside
ad-hoc-news.de
·
13 hours ago
UCB stock pre-market at EUR 203.40
ad-hoc-news.de
·
1 day ago
UCB dedicated Georgia site. UCB stock sits below EUR 206.70
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com